Solving a decades-long puzzle in leishmaniasis drug development

A breakthrough in understanding how a single-cell parasite makes ergosterol (its version of cholesterol) could lead to more effective drugs for human leishmaniasis, a parasitic disease that afflicts about 1 million people and kills about 30,000 people around the world every year.

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

news.medical.net - 05/Dec 19:41

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting...

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

news.medical.net - 05/Dec 19:41

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting...

Ayrmid Reports Promising New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease

wn.com - 06/Dec 14:29

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling...

Ayrmid Reports Promising New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease

wn.com - 06/Dec 14:29

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling...

10 Most Interesting Science News of 2025

thecekodok.com - 08/Dec 10:34

The year 2025 will see interesting developments in seeing the impact of AI in daily activities, species thought to be lost are rediscovered and gene...

Most Speakers at FDA Advisory Committee Meetings Support Drug Approval

drugs.com - 05/Dec 15:12

FRIDAY, Dec. 5, 2025 -- Most speakers attending U.S. Food and Drug Administration (FDA) Human Drug Advisory Committee meetings about new drugs or...

Most Speakers at FDA Advisory Committee Meetings Support Drug Approval

drugs.com - 05/Dec 15:12

FRIDAY, Dec. 5, 2025 -- Most speakers attending U.S. Food and Drug Administration (FDA) Human Drug Advisory Committee meetings about new drugs or...

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

oncologynews.com.au - 04:32

On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle for adults with extensive stage small cell lung...

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

oncologynews.com.au - 04:32

On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle for adults with extensive stage small cell lung...

Central Asia Has A Drug Problem, And It Is Growing Worse – Analysis

eurasiareview.com - 06/Dec 00:06

By Bruce Pannier (FPRI) -- Not long after late 1991, when the Soviet Union collapsed and Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and...

Rubriques :

Solving a decades-long puzzle in leishmaniasis drug development

Articles similaires

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

Ayrmid Reports Promising New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease

Ayrmid Reports Promising New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease

10 Most Interesting Science News of 2025

Most Speakers at FDA Advisory Committee Meetings Support Drug Approval

Most Speakers at FDA Advisory Committee Meetings Support Drug Approval

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer

Central Asia Has A Drug Problem, And It Is Growing Worse – Analysis

Les derniers communiqués